A pivotal phase III clinical study (NCT00019682) has demonstrated that in patients with advanced melanoma, the concurrent administration of the gp100 vaccine along with interleukin-2 can enhance response rates and extend PFS when compared to the use of interleukin-2 as a monotherapy [77]. The gene discussed is IL2; the disease is melanoma.